Scholar Rock - SRRK Stock Forecast, Price & News

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Scholar Rock Stock Up 6.7 %

NASDAQ:SRRK traded up $0.57 during midday trading on Tuesday, reaching $9.09. 595,955 shares of the stock traded hands, compared to its average volume of 769,203. Scholar Rock has a 12-month low of $4.32 and a 12-month high of $44.95. The business has a 50-day moving average of $6.52 and a two-hundred day moving average of $10.28. The company has a debt-to-equity ratio of 0.25, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market capitalization of $320.90 million, a PE ratio of -3.02 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK - Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). Scholar Rock had a negative net margin of 236.95% and a negative return on equity of 59.99%. The firm had revenue of $1.00 million for the quarter. During the same period last year, the firm earned ($0.84) earnings per share. The firm's revenue was down 78.2% compared to the same quarter last year. On average, equities analysts forecast that Scholar Rock will post -2.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their target price on shares of Scholar Rock from $46.00 to $37.00 in a report on Tuesday, May 24th. BMO Capital Markets cut their price target on shares of Scholar Rock from $55.00 to $43.00 in a report on Tuesday. Wedbush cut their price target on shares of Scholar Rock from $50.00 to $33.00 and set a "na" rating on the stock in a report on Tuesday, May 17th. Piper Sandler lowered their price target on shares of Scholar Rock from $28.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday, June 23rd. Finally, Truist Financial started coverage on shares of Scholar Rock in a research report on Tuesday, July 12th. They issued a "buy" rating and a $20.00 price target for the company. One equities research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $29.14.

Insider Buying and Selling at Scholar Rock

In related news, Director Amir Nashat purchased 1,197,992 shares of the business's stock in a transaction on Wednesday, June 22nd. The shares were acquired at an average price of $4.90 per share, for a total transaction of $5,870,160.80. Following the purchase, the director now owns 3,540,530 shares of the company's stock, valued at approximately $17,348,597. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.05% of the stock is currently owned by company insiders.